The Fort Worth Press - Wellgistics Management Converts $2 Million in Deferred Compensation into Equity at $0.20 per Share

USD -
AED 3.672499
AFN 66.498782
ALL 80.629676
AMD 365.091035
AOA 917.000408
ARS 1492.336499
AUD 1.414877
AWG 1.80125
AZN 1.701052
BAM 1.691649
BBD 2.00813
BDT 123.418242
BHD 0.375989
BIF 2985.079791
BMD 1
BND 1.277602
BOB 11.849673
BRL 5.083698
BSD 0.997016
BTN 94.875232
BWP 13.457596
BYN 2.968819
BYR 19600
BZD 2.00519
CAD 1.39518
CDF 2262.499098
CHF 0.808199
CLF 0.023198
CLP 912.999827
CNY 6.747602
CNH 6.743155
COP 3157.68
CRC 453.228387
CUC 1
CUP 26.5
CVE 95.372573
CZK 20.984797
DJF 177.546166
DKK 6.46806
DOP 58.20179
DZD 132.308956
EGP 49.569799
ERN 15
ETB 160.923669
EUR 0.86521
FJD 2.20855
FKP 0.74148
GBP 0.741195
GEL 2.610161
GGP 0.74148
GHS 11.700039
GIP 0.74148
GMD 73.496802
GNF 8756.649224
GTQ 7.607144
GYD 208.588851
HKD 7.845875
HNL 26.723176
HRK 6.519601
HTG 130.363707
HUF 314.212956
IDR 17801
ILS 2.99985
IMP 0.74148
INR 95.21055
IQD 1306.058902
IRR 1375550.000465
ISK 123.37984
JEP 0.74148
JMD 158.335856
JOD 0.708953
JPY 157.888997
KES 128.789741
KGS 87.449779
KHR 4049.647537
KMF 425.999543
KRW 1411.360366
KWD 0.30866
KYD 0.830861
KZT 467.275008
LAK 22510.919863
LBP 89282.792025
LKR 334.420274
LRD 179.959348
LSL 16.197552
LTL 2.95274
LVL 0.60489
LYD 6.341738
MAD 9.29222
MDL 17.337716
MGA 4254.638239
MKD 53.219738
MMK 2099.549369
MNT 3595.852714
MOP 8.056654
MRU 40.080439
MUR 46.795264
MVR 15.450064
MWK 1728.841413
MXN 17.138497
MYR 4.085099
MZN 63.904996
NAD 16.197552
NGN 1361.789707
NIO 36.690741
NOK 9.50157
NPR 151.800372
NZD 1.69811
OMR 0.382693
PAB 0.997016
PEN 3.376465
PGK 4.406003
PHP 60.814978
PKR 276.796523
PLN 3.719555
PYG 5928.296501
QAR 3.644596
RON 4.541503
RSD 101.492021
RUB 81.61994
RWF 1466.072741
SAR 3.744756
SBD 8.065696
SCR 14.449077
SDG 600.504962
SEK 9.48365
SGD 1.278665
SLE 24.60377
SOS 569.822255
SRD 37.866499
STD 20697.981008
STN 21.191022
SVC 8.723782
SZL 16.194265
THB 32.970555
TJS 9.197509
TMT 3.51
TND 2.929032
TRY 47.714698
TTD 6.757774
TWD 32.250104
TZS 2643.563029
UAH 44.653894
UGX 3714.050945
UYU 40.133201
UZS 11924.058297
VES 755.762399
VND 26204.5
VUV 118.557141
WST 2.733716
XAF 567.363231
XAG 0.015658
XAU 0.00023
XCD 2.70255
XCG 1.796912
XDR 0.705618
XOF 567.363231
XPF 103.152705
YER 238.395817
ZAR 16.14803
ZMK 9001.197294
ZMW 18.818492
ZWL 321.999592
  • CMSC

    0.0240

    21.744

    +0.11%

  • BCC

    2.3400

    86.6

    +2.7%

  • JRI

    0.1500

    12.81

    +1.17%

  • CMSD

    -0.1600

    21.82

    -0.73%

  • BCE

    -0.0200

    22.75

    -0.09%

  • GSK

    0.7900

    52.96

    +1.49%

  • BTI

    0.6000

    59.33

    +1.01%

  • RBGPF

    0.7600

    70.5

    +1.08%

  • RIO

    1.4500

    101.1

    +1.43%

  • VOD

    0.1900

    16.19

    +1.17%

  • RYCEF

    0.2300

    20.85

    +1.1%

  • RELX

    0.0485

    35.52

    +0.14%

  • BP

    -0.6000

    41.63

    -1.44%

  • AZN

    1.4100

    161.42

    +0.87%

  • NGG

    0.4700

    80.88

    +0.58%

Wellgistics Management Converts $2 Million in Deferred Compensation into Equity at $0.20 per Share
Wellgistics Management Converts $2 Million in Deferred Compensation into Equity at $0.20 per Share

Wellgistics Management Converts $2 Million in Deferred Compensation into Equity at $0.20 per Share

TAMPA, FL / ACCESS Newswire / March 19, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics"), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx into its patented blockchain-enabled smart contracts platform PharmacyChain, today announced that its President and Interim Chief Executive Officer, Prashant Patel, together with an additional participant from the Company's Board of Directors, entered into agreements with the Company to convert an aggregate of approximately $2.0 million of accrued compensation into shares of the Company's common stock at a conversion price of $0.20 per share, representing a premium to the Company's recent trading price. In connection with the conversion, the Company will issue approximately 10,000,000 shares of common stock.

Text size:

In addition, the Company issued an aggregate of 10,000,000 warrants to purchase shares of common stock at an exercise price of $0.01 per share (the "Warrants"), which were issued as additional consideration in connection with the conversion. The Warrants are exercisable immediately, have a term of 5 years from issuance, and are subject to customary anti-dilution adjustments.

This conversion, which was approved by the disinterested directors of the Board, reflects Mr. Patel's confidence in the Company's strategic direction and his commitment to creating long-term shareholder value. Further reinforcing Mr. Patel's belief in the Company's long-term success, the newly issued shares of the Company's common stock are subject to a lock-up agreement restricting transfers for a period of 6 months, subject to customary exceptions.

The structure of the transaction, including the issuance of Warrants, was designed to align management and director incentives with long-term shareholder value creation.

"I believe Wellgistics has the potential to build upon its vision and bring long lasting value to all healthcare stakeholders," said Mr. Patel. "This conversion reinforces my unwavering belief in our team, our mission, and the transformative impact we will have on the future of healthcare."

About Wellgistics Health, Inc.

Wellgistics Health (NASDAQ:WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx into its patented blockchain-enabled smart contracts platform PharmacyChain to optimize the prescription drug dispensing journey. Its integrated platform connects 6,500+ pharmacies (the "Wellgistics Pharmacy Network") and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.

For more information, visit www.wellgisticshealth.com.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or the Company's future financial or operating performance and may include, without limitation, statements regarding the expected benefits of the debt conversion transaction, including its anticipated impact on the Company's balance sheet, liquidity, capitalization, and alignment of management and director interests with those of stockholders, as well as the Company's strategic plans, growth initiatives, and long-term value creation.

In some cases, forward-looking statements can be identified by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential," "continue," or the negative of these terms or other comparable terminology. These statements are based on current expectations, estimates, and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements.

These risks and uncertainties include, without limitation, risks related to the Company's ability to realize the anticipated benefits of the debt conversion transaction; the potential dilutive impact of the issuance of common stock and warrants, including upon exercise of the warrants; the Company's ability to maintain compliance with Nasdaq listing standards; market conditions and volatility in the Company's stock price; the Company's ability to execute its business strategy and growth initiatives; and other risks and uncertainties described from time to time in the Company's filings with the U.S. Securities and Exchange Commission.

Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Wellgistics Media & Investor Contact

Media:
[email protected]

Investor Relations:
[email protected]

SOURCE: Wellgistics Health, Inc.



View the original press release on ACCESS Newswire

S.Rocha--TFWP